At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
MK-0677 +1 moredrug
Likely dose
MK-0677 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients
In Brief
A clinical study evaluating MK-0677 and Placebo for Chronic Kidney Disease and End Stage Renal Disease. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The objective of this study is to determine MK-0677 increases IGF-1 in patients with end stage renal disease (ESRD) on hemodialysis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, End Stage Renal Disease
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Merck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedNov 2006
Primary CompletionJan 2009
Study CompletionMay 2010
TodayJul 2026
First PostedNov 2, 2006
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2009
Study CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.7 years ago
Interventions
MK-0677drug
The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
Placebodrug
Placebo